BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewis LA, Rice PA, Ram S. Role of Gonococcal Neisserial Surface Protein A (NspA) in Serum Resistance and Comparison of Its Factor H Binding Properties with Those of Its Meningococcal Counterpart. Infect Immun 2019;87:e00658-18. [PMID: 30510105 DOI: 10.1128/IAI.00658-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Harrison OB, Maiden MC. Recent advances in understanding and combatting Neisseria gonorrhoeae: a genomic perspective. Fac Rev 2021;10:65. [PMID: 34557869 DOI: 10.12703/r/10-65] [Reference Citation Analysis]
2 Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA. Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology 2016;221:1110-23. [PMID: 27297292 DOI: 10.1016/j.imbio.2016.05.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
3 Baarda BI, Zielke RA, Holm AK, Sikora AE. Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates. mSphere 2021;6:e00977-20. [PMID: 33536323 DOI: 10.1128/mSphere.00977-20] [Reference Citation Analysis]
4 Jefferson A, Smith A, Fasinu PS, Thompson DK. Sexually Transmitted Neisseria gonorrhoeae Infections-Update on Drug Treatment and Vaccine Development. Medicines (Basel) 2021;8:11. [PMID: 33562607 DOI: 10.3390/medicines8020011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Shaughnessy J, Tran Y, Zheng B, DeOliveira RB, Gulati S, Song WC, Maclean JM, Wycoff KL, Ram S. Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front Immunol 2020;11:583305. [PMID: 33193396 DOI: 10.3389/fimmu.2020.583305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ngwa DN, Singh SK, Gang TB, Agrawal A. Treatment of Pneumococcal Infection by Using Engineered Human C-Reactive Protein in a Mouse Model. Front Immunol 2020;11:586669. [PMID: 33117400 DOI: 10.3389/fimmu.2020.586669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hou Y, Yan T, Cao H, Liu P, Zheng K, Li Z, Deng Q, Hu S. Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice. Int J Nanomedicine 2019;14:6601-13. [PMID: 31496701 DOI: 10.2147/IJN.S206210] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Saha S, Coady A, Sasmal A, Kawanishi K, Choudhury B, Yu H, Sorensen RU, Inostroza J, Schoenhofen IC, Chen X, Münster-Kühnel A, Sato C, Kitajima K, Ram S, Nizet V, Varki A. Exploring the Impact of Ketodeoxynonulosonic Acid in Host-Pathogen Interactions Using Uptake and Surface Display by Nontypeable Haemophilus influenzae. mBio 2021;12:e03226-20. [PMID: 33468699 DOI: 10.1128/mBio.03226-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Walter L, Sürth V, Röttgerding F, Zipfel PF, Fritz-Wolf K, Kraiczy P. Elucidating the Immune Evasion Mechanisms of Borrelia mayonii, the Causative Agent of Lyme Disease. Front Immunol 2019;10:2722. [PMID: 31849943 DOI: 10.3389/fimmu.2019.02722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
10 Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, Mörgelin M, Jacobsson S, Riesbeck K, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight 2019;4:131886. [PMID: 31661468 DOI: 10.1172/jci.insight.131886] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
11 Moore SR, Menon SS, Cortes C, Ferreira VP. Hijacking Factor H for Complement Immune Evasion. Front Immunol 2021;12:602277. [PMID: 33717083 DOI: 10.3389/fimmu.2021.602277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol 2019;10:321. [PMID: 30873172 DOI: 10.3389/fimmu.2019.00321] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Russell MW, Jerse AE, Gray-Owen SD. Progress Toward a Gonococcal Vaccine: The Way Forward. Front Immunol 2019;10:2417. [PMID: 31681305 DOI: 10.3389/fimmu.2019.02417] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]